REFERENCES
  1. Cascella M, Rajnik M, Cuomo A, et al. Features, evaluation, and treatment of coronavirus. [Updated 2020 Oct 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January 2020.
  2. Ministry of National Health Services Regulations and Coordination. COVID-19 health advisory platform. 2020. http://covid.gov.pk/. Accessed 26 December, 2020.
  3. Singh A, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: a systemic review and a clinician’s perspective. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(5):971-978. doi:10.1016/j.dsx.2020.06.054
  4. Tobaiqy M, Qashqary M, Al-Dahery S et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020;2(3):100061. doi:10.1016/j.infpip.2020.100061
  5. Isidori A, Arnaldi G, Boscaro M et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology expert opinion on steroid replacement in adrenal insufficiency. J Endocrinol Invest. 2020;43(8):1141-1147. doi:10.1007/s40618-020-01266-w
  6. Stockman L, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343. doi:10.1371/journal.pmed.0030343
  7. Arabi Y, Mandourah Y, Al-Hameed F et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757-767. doi:10.1164/rccm.201706-1172oc
  8. Horby P, Lim W, Emberson J et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. 2020. doi:10.1101/2020.06.22.20137273 [Preprint]
  9. Li H, Chen C, Hu F, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503-1511. doi:10.1038/s41375-020-0848-3